<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present here the case of a Japanese female patient with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who developed <z:mp ids='MP_0004026'>monosomy</z:mp> 7 and <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> following a treatment with recombinant human granulocyte colony-stimulating factor (rhG-CSF) </plain></SENT>
<SENT sid="1" pm="."><plain>At the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, cytogenetic analysis was 46, XX and X-inactivation/methylation analysis revealed a polyclonal pattern </plain></SENT>
<SENT sid="2" pm="."><plain>After 4 months of administration of rhG-CSF, she had 45, XX, -7 and a clonal pattern, although there were no morphological evidence of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The ratio of <z:mp ids='MP_0004026'>monosomy</z:mp> 7 to <z:mpath ids='MPATH_458'>normal</z:mpath> analyzed by fluorescence in situ hybridization decreased after discontinuation of rhG-CSF and there were still no dysplastic changes and/or increased numbers of blasts </plain></SENT>
<SENT sid="4" pm="."><plain>These results indicate that the acquisition of <z:mp ids='MP_0004026'>monosomy</z:mp> 7 following rhG-CSF treatment dose not always cause <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> to induce <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>